Paclitaxel and gemcitabine combination in a biweekly schedule in patients with advanced non small-cell lung cancer: a phase i study

Athanasiadis, A.; Roussos, George; Papakostoulis, Thomas; Athanasiadou, Daniela-Carmen; Stathopoulos, George P.

doi:10.1007/s00280-005-1009-0

Cited by 5 publications

(3 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1,2 Concurrent treatment with corticosteroids may not prevent the development of drug-induced pneumonitis. [3][4][5][6][7] Elevated WBC count in peripheral blood, elevated erythrocyte sedimentation rate, and elevated C-reactive protein levels are also common nonspecific laboratory findings. Chest imaging may show diffuse or patchy, unilateral or bilateral, ground-glass opacities or consolidations.…”

Section: Clinical Manifestations and Diagnosismentioning

confidence: 99%

Pulmonary Complications of Novel Antineoplastic Agents for Solid Tumors

Vahid

Marik

2008

Chest

223

150

View full text Add to dashboard Cite

Section: Clinical Manifestations and Diagnosismentioning

confidence: 99%

Pulmonary Complications of Novel Antineoplastic Agents for Solid Tumors

Vahid

Marik

2008

Chest

223

150

View full text Add to dashboard Cite

“…Growth factor (granulocytecolony stimulating factor [G-CSF]) support is not usually used in paclitaxel combinations. These drugs have also been evaluated in Phase I studies using a biweekly schedule [19,20]. As a single drug, a Phase I study showed that biweekly gemcitabine could be delivered in doses up to 5700 mg/m 2 [21].…”

mentioning

confidence: 99%

“…When paclitaxel and gemcitabine were combined biweekly, dose-limiting toxicities were febrile neutropenia and, in one study, alanine transaminase (ALT) elevations. Doses recommended for biweekly Phase II studies are paclitaxel 150 mg/m 2 plus gemcitabine 3000 mg/m 2 [19] or 2500 mg/m 2 [20].…”

mentioning

confidence: 99%

Gemcitabine in Combination with Paclitaxel for the Treatment of Metastatic Breast Cancer

Colomer

2005

Womens Health (Lond Engl)

View full text Add to dashboard Cite

Gemcitabine and paclitaxel are active drugs in the treatment of patients with metastatic breast cancer which seem to have synergistic anticancer activity. Seven Phase II trials of gemcitabine/paclitaxel and one Phase III trial have been published. Two dosing or admistration schedules have been preferred in the clinical development of the combinations: gemcitabine on days 1 and 8 plus paclitaxel on day 1 or 8, every 3 weeks or gemcitabine plus paclitaxel on day 1, every 2 weeks. In first-line Phase II trials, up to 71% of patients responded to gemcitabine/paclitaxel therapy. Response rates were lower among patients who had received previous chemotherapy for metastatic disease (46%). Responses were observed in patients refractory to docetaxel monotherapy. Toxicity of gemcitabine/paclitaxel regimens has been low, with infrequent neutropenia or nonhematologic toxicity. In the randomized Phase III registration trial, the gemcitabine/paclitaxel combination demonstrated a clear advantage over paclitaxel alone in terms of the primary end point of survival and other efficacy end points, with manageable toxicity. Gemcitabine/paclitaxel showed a survival advantage of approximately 22% over paclitaxel alone (hazard ratio of 0.775). Gemcitabine plus paclitaxel represents an active and well-tolerated treatment alternative for first-line treatment of anthracycline-treated metastatic breast cancer. Triplet combinations, in which an anthracycline or trastuzumab are added to gemcitabine/paclitaxel, are being explored in the metastatic and neoadjuvant settings with excellent results. In addition, gemcitabine/paclitaxel is being evaluated in two large adjuvant multicenter studies.

show abstract

Microtubule stabilizing agents: Their molecular signaling consequences and the potential for enhancement by drug combination

Bergstralh

Ting

2006

Cancer Treatment Reviews

View full text Add to dashboard Cite

Paclitaxel and gemcitabine combination in a biweekly schedule in patients with advanced non small-cell lung cancer: a phase i study

Abstract: Paclitaxel and gemcitabine can be safely administered at a high dose intensity on an every-other-week schedule. The recommended phase II dose is paclitaxel 175 mg/m2 and gemcitabine 2,500 mg/m2.

Cited by 5 publications

References 15 publications

Pulmonary Complications of Novel Antineoplastic Agents for Solid Tumors

Pulmonary Complications of Novel Antineoplastic Agents for Solid Tumors

Gemcitabine in Combination with Paclitaxel for the Treatment of Metastatic Breast Cancer

Microtubule stabilizing agents: Their molecular signaling consequences and the potential for enhancement by drug combination

Contact Info

Product

Resources

About